Seroquel in Bipolar Depression versus Lithium
Study identifier:D1447C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks & Quetiapine in Continuation (abbreviated)
Medical condition
Bipolar Disorder
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)
Sex
All
Actual Enrollment
672
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Aug 2005
Primary Completion Date: -
Study Completion Date: 01 May 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Seroquel Medical Science Director
AstraZeneca
